PDPOIETIN IN COMPARISON WITH EPREX IN TREATMENT OF ANEMIC PATIENTS ON HEMODIALYSIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ARGANI H.; OSAREH SH.; TABIBAN S.; GANJI M.R.; NAFAR M.; ABDI E.A.; ALIPOUR B.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Kidney Diseases Year:2009 | Volume:3 | Issue:3 Page(s): 145-150

Download Full-Text

View:

620

Download:

179

Cites:

Information Journal Paper

Title

PDPOIETIN IN COMPARISON WITH EPREX IN TREATMENT OF ANEMIC PATIENTS ON HEMODIALYSIS

Author(s)

Keywords

END-STAGE RENAL DISEASE

ANEMIA

RECOMBINANT ERYTHROPOIETIN

Abstract

Introduction. PDpoietin is a RECOMBINANT ERYTHROPOIETIN alfa that has been introduced by a manufacturer in Iran. We assessed the effectiveness and complications of PDpoietin in comparison with Eprex in anemic patients on hemodialysis. Materials and Methods. This clinical trial was performed in a multicenter setting. Patients with a hemoglobin level less than 12 g/dL were assigned into 2 groups in order to receive either Eprex (Janssen Cilag) or PDpoietin (Pooyesh Darou) for 3 months. Results. Forty-one and 34 patients completed the study in the PDpoietin and Eprex groups, respectively. The mean hemoglobin levels at baseline were not significantly different between the two groups of patients with PDpoietin and Eprex. In both groups, hemoglobin levels increased significantly, but there were no significant differences between the two groups at months 1, 2, and 3. At the end of the study, the mean hemoglobin levels reached 11.6±1.7 g/dL and 11.8±1.9 g/dL, respectively (P = .002; P = .01). The mean hemoglobin per cumulative of drug dose index (hemoglobin/[erythropoietin dose/1000 × injections per month]) was not significantly different between the two groups at different treatment stages, and it did not change significantly in each group during the course of the study. No serious complications were reported.Conclusions. Eprex and PDpoietin could equally increase the hemoglobin levels with no significant complication. Therefore, PDpoietin can be used for treatment of ANEMIA in patients on dialysis, and the patients will have the advantages of its availability and low price.

Cites

No record.

References

Cite

APA: Copy

ARGANI, H., OSAREH, SH., TABIBAN, S., GANJI, M.R., NAFAR, M., ABDI, E.A., & ALIPOUR, B.. (2009). PDPOIETIN IN COMPARISON WITH EPREX IN TREATMENT OF ANEMIC PATIENTS ON HEMODIALYSIS . IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), 3(3), 145-150. SID. https://sid.ir/paper/308740/en

Vancouver: Copy

ARGANI H., OSAREH SH., TABIBAN S., GANJI M.R., NAFAR M., ABDI E.A., ALIPOUR B.. PDPOIETIN IN COMPARISON WITH EPREX IN TREATMENT OF ANEMIC PATIENTS ON HEMODIALYSIS . IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)[Internet]. 2009;3(3):145-150. Available from: https://sid.ir/paper/308740/en

IEEE: Copy

H. ARGANI, SH. OSAREH, S. TABIBAN, M.R. GANJI, M. NAFAR, E.A. ABDI, and B. ALIPOUR, “PDPOIETIN IN COMPARISON WITH EPREX IN TREATMENT OF ANEMIC PATIENTS ON HEMODIALYSIS ,” IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), vol. 3, no. 3, pp. 145–150, 2009, [Online]. Available: https://sid.ir/paper/308740/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops